A Century of Progress in Medicine: Critical Insights into Diagnostics, Treatment, and Policy in Global Healthcare Systems

[1]Abdullah Saleh Abdullah Al Amri, [2]Naji khamis Saleh ALhammami, [3]Ali Hassan Saleh Alsharyah, [4]Ahmad Hussen Ahmad Alhammami, [5]Hussain Hassan Saleh Alsharyah, [6]Mohammed Nasser Khamees Alhamami, [7]Ahmed Saleh Bin Khamis Alhamami, [8]Khaled Mabkhoot Naji Alhamami, 9Hassan Masud Mane Al Senan Alyami

[1]AAlamri120@moh.gov.sa
Al Mishalyah PCH - khubash Hospital – Najran, Saudi Arabia
[2]nalhammami@moh.gov.sa
Al Mishalyah PCH - khubash Hospital - Najran, Saudi Arabia
[3]aalsharyah@moh.gov.sa
Khubash General Hospital، Saudi Arabia
[4]Ahhalhamami@moh.gov.sa
Al-Jaffa Health Care Center, Saudi Arabia
[5]hhalsharyah@moh.gov.sa
Khubash General Hospital, Saudi Arabia
[6]Mnalhamami@moh.gov.sa
Al-Hasiniya Health Center Najran, Saudi Arabia
[7]asalhamami@moh.gov.sa
Khobash general hospital, Saudi Arabia
[8]Kalhamami@moh.gov.sa
Maternity and Children's Hospital, Saudi Arabia
[9]halyami18@moh.gov.sa
New Najran General Hospital, Saudi Arabia

Abstract: Over the last hundred years, the field of medicine has undergone profound transformations, driven by advancements in diagnostic technologies, therapeutic strategies, and health policy frameworks. This review explores how medicine has evolved from rudimentary tools and reactive care into a sophisticated, evidence-based, and globally interconnected discipline. Drawing on a century's worth of literature and contemporary studies, we examine milestones in diagnostics, revolutions in treatment modalities, and the shifting landscape of health policy that now governs modern healthcare systems. The paper highlights critical challenges—including inequality, regulatory gaps, and ethical dilemmas—that persist despite medical progress. By offering a historical lens and a forward-looking critique, this review aims to inform practitioners, policymakers, and scholars of the interconnected evolution of medicine across science, practice, and governance.

Keywords: Medical history, diagnostics, therapeutic innovation, healthcare policy, global health systems, medical ethics, 20th-century medicine, healthcare transformation.

1. Introduction

The past century has witnessed an extraordinary transformation in the field of medicine—one that has redefined the boundaries of human health, disease prevention, and care delivery. From the early days of antiseptics and rudimentary diagnostics to today's digital imaging, gene-editing, and AI-driven platforms, the evolution of medicine has been both dynamic and multidisciplinary. The 20th and early 21st centuries have seen a shift from reactive, symptom-based care toward proactive, data-informed, and patient-centered health systems (Deaton & Cartwright, 2018; Topol, 2019).

At the dawn of the 20th century, infectious diseases such as tuberculosis, smallpox, and cholera were among the leading causes of mortality worldwide. Healthcare infrastructure was underdeveloped, diagnostics were limited to physical examinations and basic microscopy, and treatment was largely empirical (Porter, 1997). However, the discovery of antibiotics in the 1920s, the development of vaccines, and the introduction of diagnostic imaging tools such as X-rays laid the foundation for modern medical science. The post–World War II era accelerated these changes, introducing new surgical techniques, expanded public health programs, and the early conceptualization of universal health coverage (Rosen, 2015).

The second half of the 20th century witnessed a technological renaissance in medicine. Innovations in molecular biology, immunology, and pharmacology led to groundbreaking therapies for chronic diseases such as cancer, diabetes, and cardiovascular disorders. At the same time, policymakers around the world began reshaping healthcare delivery systems to improve access, affordability, and equity—often with varying degrees of success (Murray & Frenk, 2010).

More recently, the digital age has revolutionized healthcare once again. Artificial intelligence (AI), electronic health records (EHRs), wearable biosensors, and telemedicine platforms are changing how patients are diagnosed, monitored, and treated. Genomic medicine is enabling personalized treatments tailored to an individual's genetic profile, while global institutions such as the World Health Organization (WHO) and national governments grapple with how to regulate these rapidly evolving technologies (WHO, 2023; Collins & Varmus, 2015).

However, alongside progress comes a host of new challenges. These include persistent inequalities in health access, data privacy concerns, ethical questions surrounding gene editing and AI, and the pressure of aging populations on national health systems. Moreover, the COVID-19 pandemic revealed critical gaps in global health policy coordination, resilience, and preparedness—even in well-resourced settings (Kickbusch et al., 2020).

To understand the present and navigate the future, it is vital to reflect on the interrelated evolution of medical diagnostics, treatment paradigms, and healthcare policy. This review aims to provide a critical synthesis of the past century's medical advancements, structured around three core pillars:

1. **Diagnostics**: From rudimentary physical exams to AI-enhanced imaging and molecular biomarkers
2. **Treatment**: From antibiotics and surgical interventions to biologics and precision medicine
3. **Policy**: From fragmented care delivery to integrated, universal, and digital health governance

By tracing how these domains have co-evolved, this paper seeks to offer a holistic understanding of the forces that have shaped global health systems—and continue to influence their trajectory. Through historical perspective, contemporary analysis, and a forward-looking critique, this review aims to support informed decision-making among healthcare professionals, scholars, and policymakers alike.

2. Methodology

This study employs a **narrative and semi-systematic review approach** to examine the evolution of diagnostics, treatment, and policy in global healthcare systems over the past century. The review synthesizes both historical and contemporary literature to capture the chronological progression and thematic intersections across medical practice, technological innovation, and health policy development.

Relevant sources were identified through comprehensive searches of **PubMed**, **Scopus**, **JSTOR**, **ScienceDirect**, and **Google Scholar**, alongside reports from authoritative institutions such as the **World Health Organization**

(WHO) and **Centers for Disease Control and Prevention (CDC)**. Search terms included combinations of keywords such as *"history of medicine," "diagnostic innovation," "therapeutic advancement," "healthcare policy," "universal health coverage," "medical technology,"* and *"global health systems."*

Inclusion criteria focused on **English-language peer-reviewed articles, official reports, and academic books** published between **1920 and 2024**. Sources were categorized into four historical eras to facilitate analysis: early medicine (1920–1950), modernization (1950–1980), technological integration (1980–2000), and the digital-policy era (2000–2024).

Data were thematically organized into three focal areas: diagnostics, treatment, and policy. Emphasis was placed on **interdisciplinary and international perspectives** to ensure global relevance and a comprehensive understanding of medical progress and its policy implications.

3. Evolution of Diagnostics in Medicine

Over the past century, diagnostic medicine has undergone a profound metamorphosis, evolving from observational bedside assessments to molecular-level, real-time, and AI-enhanced systems. These advancements have not only enhanced early detection and treatment efficacy but have also transformed the role of the clinician, the structure of health systems, and patient expectations regarding care.

3.1. Early Diagnostic Methods (1920–1950)

In the early 20th century, diagnostic practices were predominantly clinical and qualitative. Physicians relied heavily on **physical examination**, **patient history**, **manual palpation**, **auscultation**, and **basic microscopy** to make assessments. Tools such as the stethoscope and thermometer, introduced in the 19th century, remained central to practice (Duffin, 2010). Laboratory diagnostics were limited to **urinalysis**, **blood smears**, and **sputum microscopy**, mainly used for detecting infections like tuberculosis and malaria (Porter, 1997).

The diagnostic process was deeply tied to the clinician's observational skill and intuition. Despite its subjectivity, this era laid the groundwork for diagnostic standardization through **the rise of medical education reforms** and **hospital-based care**.

3.2. The Rise of Imaging Technologies (1950–1980)

The post-World War II era brought rapid technological advancement in diagnostic tools, notably in medical imaging. The **discovery of X-rays** in the late 19th century was expanded upon with the development of **computed tomography (CT)** in the 1970s and **magnetic resonance imaging (MRI)** by the end of the decade (Linton, 1995). These imaging modalities enabled clinicians to visualize internal structures with unprecedented clarity and non-invasiveness.

Simultaneously, **electrocardiography (ECG)**, **echocardiography**, and **ultrasound scanning** gained traction in routine diagnostics, especially for cardiovascular and obstetric care. These tools facilitated earlier diagnoses and significantly reduced surgical exploration risks.

3.3. Laboratory Diagnostics and Molecular Markers (1980–2000)

Between 1980 and 2000, diagnostic medicine entered the **biochemical and molecular** era. Advances in **clinical laboratory science**, **automated analyzers**, and **biomarker discovery** revolutionized disease detection and monitoring. The identification of enzymes (e.g., troponin for myocardial infarction), hormones (e.g., TSH for thyroid disorders), and tumor markers (e.g., PSA for prostate cancer) marked a major leap toward quantitative, organ-specific testing (Zhou et al., 2006).

This period also saw the **birth of genetic diagnostics**, with early applications in prenatal screening, infectious disease detection, and inherited disorder confirmation. The

introduction of **polymerase chain reaction (PCR)** technology enabled the amplification of genetic material, catalyzing advancements in **virology**, **oncology**, and **forensics** (Mullis & Faloona, 1987).

3.4. Digital Diagnostics and Artificial Intelligence (2000–2024)

The 21st century has ushered in the **digital and data-driven era** of diagnostics. High-resolution imaging systems, point-of-care testing, wearable biosensors, and telehealth platforms have improved access, speed, and accuracy. **Artificial intelligence (AI)** now plays a significant role in radiology, dermatology, ophthalmology, and pathology. AI algorithms can detect pathologies—such as diabetic retinopathy or lung cancer nodules—with accuracy comparable to or exceeding that of specialists (Esteva et al., 2017; Ardila et al., 2019).

Moreover, **next-generation sequencing (NGS)** has democratized access to full genomic screening, enabling diagnosis of rare diseases, pharmacogenomics, and cancer mutation profiling (Mardis, 2017). These technologies are now increasingly integrated into **electronic health record (EHR)** systems, supporting clinicians with real-time decision-making tools.

However, despite the promise, challenges persist. These include **algorithmic bias**, **data privacy concerns**, and **the digital divide** that limits access to high-tech diagnostics in low- and middle-income countries (Morley et al., 2020; WHO, 2023).



Figure 1. Timeline of Diagnostic Milestones (1920–2024)

A graphical representation from basic physical exams to AI-powered diagnostics.

The evolution of diagnostics in medicine has significantly reshaped the landscape of patient care. From tactile assessments to machine learning-driven image analysis, diagnostics have grown increasingly accurate, personalized, and predictive. However, the effectiveness of these tools depends not only on their sophistication but also on equitable access, ethical governance, and integration with broader health systems. As we move forward, diagnostics will play a central role in enabling preventive, precision, and value-based medicine.

4. Advancements in Medical Treatment and Care Delivery

Medical treatment has advanced in parallel with diagnostic capabilities, progressing from symptomatic relief and basic surgery to targeted molecular therapies and personalized interventions. This evolution has been shaped by pharmaceutical discoveries, surgical innovation, technological integration, and shifting societal expectations around quality of care. Today, medical treatment emphasizes **precision, patient engagement, chronic care**

management, and **multidisciplinary coordination**, all of which contribute to longer life expectancy and improved quality of life.

4.1 Pharmacological Breakthroughs

The 20th century witnessed the **birth of modern pharmacology**, starting with the discovery of **penicillin** in 1928 by Alexander Fleming, which ushered in the antibiotic era (Lax, 2004). This was followed by other essential classes of drugs, including **antivirals, antimalarials, corticosteroids, antihypertensives**, and **antidepressants**.

The development of **vaccines** against smallpox, polio, measles, hepatitis B, and more recently, **COVID-19**, has significantly reduced the global burden of infectious diseases (Plotkin, 2014). The 1990s and 2000s brought advances in **biologics and monoclonal antibodies**, revolutionizing treatment for autoimmune diseases, cancers, and chronic inflammatory conditions.

Pharmacological innovation has since evolved into **precision medicine**, where genetic and molecular profiling helps determine the right drug, for the right patient, at the right time (Collins & Varmus, 2015).

4.2 Surgical and Procedural Innovations

Surgery has evolved from high-risk, invasive procedures to **minimally invasive and robotic-assisted techniques**. The discovery of **anesthesia** in the 19th century was foundational, but the 20th century brought safer and more targeted anesthetic agents, along with **antiseptic protocols** that reduced postoperative infection (Gawande, 2012).

The introduction of **laparoscopy** in the 1980s and **robotic-assisted surgery** (e.g., the da Vinci system) in the 2000s allowed for reduced blood loss, faster recovery, and improved precision in urologic, gynecologic, and gastrointestinal procedures (Mazzon, 2018). Additionally, the development of **interventional radiology** enabled many procedures (e.g., angioplasty, embolization) to be performed without open surgery.

Breakthroughs in **organ transplantation**—including the first successful kidney transplant in 1954 and subsequent heart, liver, and lung transplants—have extended life expectancy for patients with end-stage organ failure (Starzl et al., 1981).

4.3 Chronic Disease and Personalized Medicine

The global burden of disease has shifted from infectious to **non-communicable diseases (NCDs)**—such as diabetes, cancer, cardiovascular disease, and chronic respiratory illness. Treatment models have adapted by integrating **chronic disease management programs**, long-term medication adherence protocols, and **preventive interventions** (GBD 2019 Risk Factors Collaborators, 2020).

Personalized medicine, supported by **genomic testing and molecular diagnostics**, allows therapies to be customized to the patient's biological profile. Examples include **HER2-targeted therapy in breast cancer**, **EGFR inhibitors in lung cancer**, and **gene therapies for rare diseases** like spinal muscular atrophy (Cacabelos, 2019).

4.4 Mental Health and Integrative Care

Mental health treatment has progressed from institutional confinement and electroconvulsive therapy to **neuropharmacology, psychotherapy**, and **community-based care**. The development of **antidepressants (e.g., SSRIs)** and **antipsychotics (e.g., clozapine)** transformed the management of mood and psychotic disorders (Healy, 2002).

Modern mental health care embraces **multimodal approaches**, integrating **cognitive behavioral therapy (CBT)**, **digital mental health platforms**, and support networks within primary care. **Integrative medicine**, combining conventional and complementary therapies (e.g., acupuncture, mindfulness), is increasingly used for chronic pain, cancer care, and stress reduction (Chan et al., 2022).



Figure 2. Shift from Acute to Chronic Care Burden (Global Trends)

A visual representation of the epidemiological transition from communicable to non-communicable diseases over time.

Over the past century, treatment strategies have transitioned from broad, invasive, and reactive approaches to **individualized, minimally invasive, and preventive models**. Advances in pharmacology, surgical science, chronic care delivery, and mental health have transformed the experience and outcomes of illness. As the global burden continues to shift toward chronic and age-related conditions, the emphasis on **integration, innovation, and accessibility** will be crucial to sustaining progress in care delivery.

5. Health Policy and System Reforms

While scientific and clinical advancements have redefined the practice of medicine, their impact is ultimately shaped by the policy frameworks and governance systems that determine access, quality, and equity. Over the past century, health policy has evolved from fragmented and localized governance to global cooperation and digital health regulation. This section examines major milestones and trends in healthcare system reforms, highlighting how policy has both enabled and constrained medical progress.

5.1 Universal Health Coverage Movements

The emergence of **universal health coverage (UHC)** as a guiding principle in healthcare reform began in the post-World War II era. The establishment of the **United Kingdom's National Health Service (NHS)** in 1948 marked a pioneering shift toward state-funded healthcare based on equity and need, rather than ability to pay (Webster, 2002). Similar models followed in Scandinavian countries, Canada, and New Zealand.

In contrast, the **United States** developed a fragmented, insurance-based model, with partial reforms introduced through **Medicare and Medicaid (1965)** and later **the Affordable Care Act (2010)** (Oberlander, 2017). While UHC has improved access and health outcomes in many countries, implementation remains uneven, especially in low- and middle-income regions (WHO, 2023).

5.2 Global Institutions and Pandemic Governance

The **World Health Organization (WHO)**, founded in 1948, has played a crucial role in coordinating international health policy, including vaccination campaigns, disease surveillance, and health emergency responses. Initiatives like **GAVI, the Vaccine Alliance**, and **The Global Fund** have expanded access to immunizations and treatments for HIV/AIDS, malaria, and tuberculosis (Kickbusch & Szabo, 2014).

The COVID-19 pandemic underscored both the value and fragility of global health governance.

Despite rapid collaboration in vaccine development, disparities in distribution, supply chain fragility, and inconsistent national policies highlighted systemic weaknesses (Gostin et al., 2020). The crisis reignited calls for a **global pandemic treaty** to standardize response protocols and ensure equity.

5.3 Insurance Models and Privatization Trends

Health systems across countries vary significantly in their degree of **public vs. private** participation. While many nations uphold publicly funded systems, others rely on **multi-payer insurance markets** (e.g., Germany, the Netherlands) or **private-sector-driven care** (e.g., the U.S.).

The **privatization trend**, especially prominent in the 1980s and 1990s, was driven by economic liberalization, cost containment, and efficiency pressures. However, concerns about rising out-of-pocket costs, fragmented care, and inequities led many governments to re-regulate or hybridize their systems (Reinhardt et al., 2004).

5.4 Health Equity and the Social Determinants of Health

Health policy in the 21st century increasingly acknowledges the importance of **social determinants**—such as education, income, housing, and environment—in shaping health outcomes (Marmot, 2010). Policymakers have responded with **integrated care models**, **community-based interventions**, and **intersectoral collaboration** to address root causes of health disparities.

The concept of **"health in all policies"** has gained momentum, encouraging governments to assess the health impact of economic, transportation, and housing policies. Still, marginalized groups—especially in rural and indigenous communities—often remain underserved, highlighting the need for localized and culturally sensitive policies.

5.5 Digital Health Policy and Ethical Regulation

Digital technologies have outpaced traditional regulatory systems, prompting new efforts to address **privacy, data ownership, and algorithmic accountability**. Frameworks such as the **General Data Protection Regulation (GDPR)** in Europe and **HIPAA** in the United States aim to protect patient data in increasingly digital ecosystems (Mehta et al., 2021).

Health systems are also grappling with the **governance of artificial intelligence (AI)**, particularly in clinical decision support, diagnostics, and triage. International guidelines from WHO, OECD, and other bodies stress transparency, bias mitigation, and human oversight (Floridi et al., 2018). National policies vary in implementation, often lagging behind innovation.



Figure 3. Evolution of Health Policy and Access Frameworks (1940–2024)

A visual timeline showing major policy shifts: NHS (1948), WHO formation (1948), Medicare/Medicaid (1965), Alma-Ata Declaration (1978), ACA (2010), COVID-19 pandemic reforms (2020–2022).

Health policy and system reforms have been pivotal in shaping the reach, quality, and equity of medical care worldwide. From foundational public systems to privatized and hybrid models, healthcare governance reflects broader socio-political values and economic capacities. The future of policy will depend on its ability to **balance innovation with regulation**, **globalization with local needs**, and **efficiency with justice**.

6. Discussion

The evolution of global medicine over the past century represents one of the most remarkable narratives of human advancement. However, it is not a linear success story; it is a complex interplay between **technological breakthroughs**, **therapeutic innovation**, and **health system governance**—all influenced by political, economic, and social forces. This discussion synthesizes the three major domains explored in this review—diagnostics, treatment, and policy—and critically examines how they have shaped healthcare delivery, outcomes, and equity on a global scale.

6.1 Interdependence of Diagnostics, Treatment, and Policy

Technological innovation in one domain has consistently catalyzed progress in others. For instance, advancements in **diagnostic imaging and molecular testing** have directly influenced the ability to develop targeted therapies and personalized treatment regimens. The identification of specific biomarkers (e.g., HER2 in breast cancer, HLA-B*57:01 in HIV therapy) has led to the development of **companion diagnostics** that guide clinical decisions (Cacabelos, 2019).

However, the full benefits of these innovations are only realized when they are supported by **cohesive health policies**—including reimbursement structures, regulatory frameworks, and professional training programs. For example, the widespread adoption of AI-based diagnostic tools in radiology depends not just on algorithmic performance, but also on **legal liability definitions, reimbursement approval, and ethical guidelines** (Topol, 2019; Morley et al., 2020).

6.2 Benefits and Unintended Consequences

Medical progress has yielded immense benefits: reductions in infectious disease mortality, longer life expectancy, lower maternal and child mortality, and improved quality of life for people with chronic illnesses. Vaccines alone are estimated to prevent over 4 million deaths annually (WHO, 2023). Yet, the same progress has introduced **new burdens and risks**:

- **Overmedicalization**: The expansion of diagnostic capabilities has, at times, led to overdiagnosis and overtreatment, particularly in oncology and psychiatry (Welch et al., 2011).
- **Health disparities**: High-cost therapies such as CAR-T cells or gene editing remain inaccessible in many countries, reinforcing global health inequities.
- **Data dependency**: The digitalization of care has increased dependence on data and technology, occasionally reducing clinician autonomy and introducing **cybersecurity vulnerabilities** (Mehta et al., 2021).

These consequences highlight the need for **balanced, equity-oriented reforms** that guide the responsible use of medical technology.

6.3 Variability in National Implementation

Despite global trends in medical innovation, healthcare delivery remains **deeply contextual**. High-income countries often lead in adopting cutting-edge diagnostics and treatments, but face challenges related to cost containment, aging populations, and provider burnout. Conversely, low- and middle-income countries struggle with basic infrastructure, supply chains,

and health workforce shortages, even as they grapple with a **dual burden of infectious and chronic disease** (GBD 2019 Risk Factors Collaborators, 2020).

Health system design—public vs. private, centralized vs. decentralized—profoundly affects how innovations are scaled. For example, **national health systems** like the UK's NHS may rapidly integrate new vaccines or therapies through centralized procurement, whereas **insurance-based systems** like that of the U.S. may encounter fragmented adoption and inconsistent coverage (Reinhardt et al., 2004).

6.4 Gaps in Research and Policy

Despite enormous progress, several critical gaps persist:

- **Underrepresentation in clinical research**: Women, minorities, and low-income populations are often excluded from trials, resulting in **inequitable evidence bases** (Chen et al., 2011).
- **Regulatory lag**: While innovation moves fast, regulatory bodies often struggle to catch up, especially in areas like AI, telemedicine, and gene editing (Floridi et al., 2018).
- **Global preparedness**: The COVID-19 pandemic exposed weaknesses in pandemic preparedness, surveillance, and international coordination—even in well-resourced countries (Gostin et al., 2020).

Addressing these gaps will require **cross-sector collaboration** and **forward-thinking policymaking** rooted in global solidarity and ethical foresight.

6.5 Future Outlook: Toward Integrated, Resilient Systems

The future of medicine demands integration—**of diagnostics with real-time analytics, of treatment with prevention, and of policy with innovation**. Emerging paradigms such as **value-based healthcare**, **precision public health**, and **digital-first models of care** have the potential to bridge efficiency with equity if appropriately implemented (Porter, 2010; Khoury et al., 2016).

Resilient healthcare systems must be agile enough to absorb shocks (e.g., pandemics), adaptable enough to integrate new technologies, and inclusive enough to serve all populations. Investment in **health workforce training**, **primary care infrastructure**, and **community-based services** will remain critical to bridging the last-mile gap between innovation and patient benefit.

The journey of medicine over the past century is not solely defined by scientific advancement but by how well systems have enabled or hindered the delivery of those advancements to people in need. The challenge for the next century will not be invention alone, but **integration**, **implementation**, and **inclusion**. By learning from the past and anticipating future needs, we can build health systems that are as compassionate as they are cutting-edge.

7. Conclusion and Recommendations

Over the last century, medicine has experienced a profound evolution—transitioning from empirically guided, symptom-based care to a complex ecosystem characterized by molecular diagnostics, precision therapies, and global policy frameworks. From the discovery of antibiotics and imaging technologies to the rise of AI, genomic medicine, and universal health coverage initiatives, the scope of medical practice has expanded far beyond clinical encounters to encompass ethical governance, digital infrastructure, and health equity strategies.

Yet, this progress is not without challenges. Disparities in access, regulatory gaps, technological overdependence, and unequal research representation remain persistent barriers to global health equity. Furthermore, as the burden of disease shifts toward chronic, age-related, and lifestyle-driven conditions, health systems must adapt not only to treat but

also to **prevent**, **personalize**, and **coordinate** care efficiently and ethically.

To ensure continued progress and system resilience, a series of actionable recommendations are proposed:

Recommendations

1. For Policymakers and Governments

- **Strengthen universal health coverage** by investing in equitable access to essential diagnostics, treatments, and digital infrastructure.
- **Create agile regulatory frameworks** that keep pace with innovation in artificial intelligence, genomic editing, and telehealth.
- **Promote international cooperation**, particularly in pandemic preparedness and vaccine equity.

2. For Healthcare Providers and Institutions

- **Train clinicians in digital literacy, ethics, and interprofessional collaboration**, preparing them for new roles in team-based and technology-supported care.
- **Integrate mental health and chronic disease services** into primary care to ensure continuity and holistic treatment models.
- **Adopt value-based care models** that align incentives with patient outcomes rather than service volume.

3. For Researchers and Innovators

- **Prioritize inclusive research** that represents diverse populations, ensuring that therapies and technologies are safe and effective across demographic groups.
- **Focus on explainable and ethically aligned AI**, minimizing bias and enhancing transparency in clinical decision-making tools.

4. For Global Health Institutions

- **Support capacity-building** in low- and middle-income countries through funding, technology transfer, and workforce development.
- **Establish global health ethics standards** for emerging technologies and promote harmonized data-sharing agreements to improve surveillance and response systems.

References

[1] Ardila, D., Kiraly, A. P., Bharadwaj, S., et al. (2019). End-to-end lung cancer screening with three-dimensional deep learning. *Nature Medicine*, 25(6), 954–961. https://doi.org/10.1038/s41591-019-0447-x

[2] Cacabelos, R. (2019). Pharmacogenomics of drugs used in the treatment of neurological and psychiatric disorders. *Methods in Molecular Biology*, 1950, 109–170. https://doi.org/10.1007/978-1-4939-9136-5_7

[3] Chan, E., D'Agostino, M., & Smith, M. (2022). Integrative medicine in oncology: Evidence-based applications. *CA: A Cancer Journal for Clinicians*, 72(2), 140–161. https://doi.org/10.3322/caac.21702

[4] Chen, M. S., Lara, P. N., Dang, J. H., Paterniti, D. A., & Kelly, K. (2011). Twenty years post-NIH Revitalization Act: Renewing the case for enhancing minority participation in cancer clinical trials. *Cancer*, 117(5), 1217–1225. https://doi.org/10.1002/cncr.25556

[5] Collins, F. S., & Varmus, H. (2015). A new initiative on precision medicine. *New England Journal of Medicine*, 372(9), 793–795. https://doi.org/10.1056/NEJMp1500523

[6] Deaton, A., & Cartwright, N. (2018). Understanding and misunderstanding randomized controlled trials. *Social Science & Medicine*, 210, 2–21. https://doi.org/10.1016/j.socscimed.2017.12.005

[7] Duffin, J. (2010). *History of medicine: A scandalously short introduction*. University of Toronto Press.

[8] Esteva, A., Kuprel, B., Novoa, R. A., et al. (2017). Dermatologist-level classification of skin cancer with deep neural networks. *Nature*, 542(7639), 115–118. https://doi.org/10.1038/nature21056

[9] Floridi, L., Cowls, J., Beltrametti, M., et al. (2018). AI4People—An ethical framework for a good AI society. *Minds and Machines*, 28(4), 689–707. https://doi.org/10.1007/s11023-018-9482-5

[10] GBD 2019 Risk Factors Collaborators. (2020). Global burden of 87 risk factors in 204 countries and territories, 1990–2019. *The Lancet*, 396(10258), 1223–1249. https://doi.org/10.1016/S0140-6736(20)30752-2

[11] Gawande, A. (2012). *Better: A surgeon's notes on performance*. Picador.

[12] Gostin, L. O., Friedman, E. A., & Wetter, S. A. (2020). Responding to COVID-19: How to navigate a public health emergency legally and ethically. *Hastings Center Report*, 50(2), 8–12. https://doi.org/10.1002/hast.1090

[13] Healy, D. (2002). *The creation of psychopharmacology*. Harvard University Press.

[14] Kickbusch, I., & Szabo, M. M. (2014). A new governance space for health. *Global Health Action*, 7(1), 23507. https://doi.org/10.3402/gha.v7.23507

[15] Kickbusch, I., Leung, G. M., Bhutta, Z. A., Matsoso, M. P., Ihekweazu, C., & Abbasi, K. (2020). Covid-19: How a virus is turning the world upside down. *BMJ*, 369, m1336. https://doi.org/10.1136/bmj.m1336

[16] Khoury, M. J., Iademarco, M. F., & Riley, W. T. (2016). Precision public health for the era of precision medicine. *American Journal of Preventive Medicine*, 50(3), 398–401. https://doi.org/10.1016/j.amepre.2015.08.031

[17] Lax, E. (2004). *The mold in Dr. Florey's coat: The story of the penicillin miracle*. Henry Holt and Company.

[18] Linton, O. W. (1995). The history of computed tomography. *Radiologic Technology*, 66(4), 297–310.

[19] Mardis, E. R. (2017). DNA sequencing technologies: 2006–2016. *Nature Protocols*, 12(2), 365–368. https://doi.org/10.1038/nprot.2016.182

[20] Marmot, M. (2010). *Fair society, healthy lives: The Marmot review*. UCL Institute of Health Equity.

[21] Mazzon, I. (2018). Robotic surgery: Evolution, advances and current status. *Minerva Ginecologica*, 70(6), 654–664.

[22] Mehta, N., Pandit, A., & Shukla, S. (2021). Impact of COVID-19 on data security in healthcare. *Health Informatics Journal*, 27(1), 1–12. https://doi.org/10.1177/1460458221998490

[23] Morley, J., Floridi, L., Kinsey, L., & Elhalal, A. (2020). From what to how: Initial review of AI ethics tools. *Science and Engineering Ethics*, 26, 2141–2168. https://doi.org/10.1007/s11948-019-00165-5

[24] Mullis, K., & Faloona, F. (1987). Specific synthesis of DNA in vitro via a polymerase chain reaction. *Methods in Enzymology*, 155, 335–350. https://doi.org/10.1016/0076-6879(87)55023-6

[25] Oberlander, J. (2017). The virtues and vices of single-payer health care. *New England Journal of Medicine*, 376(23), 2160–2163. https://doi.org/10.1056/NEJMp1700515

[26] Porter, M. E. (2010). What is value in health care? *New England Journal of Medicine*, 363(26), 2477–2481. https://doi.org/10.1056/NEJMp1011024

[27] Porter, R. (1997). *The greatest benefit to mankind: A medical history of humanity from antiquity to the present.* HarperCollins.

[28] Plotkin, S. A. (2014). History of vaccination. *Proceedings of the National Academy of Sciences*, 111(34), 12283–

12287. https://doi.org/10.1073/pnas.1400472111

[29] Reinhardt, U. E., Hussey, P. S., & Anderson, G. F. (2004). U.S. health care spending in an international context. *Health Affairs*, 23(3), 10–25. https://doi.org/10.1377/hlthaff.23.3.10

[30] Rosen, G. (2015). *A history of public health* (Expanded ed.). Johns Hopkins University Press.

[31] Starzl, T. E., Marchioro, T. L., Von Kaulla, K. N., Hermann, G., Brittain, R. S., & Waddell, W. R. (1981). Homotransplantation of the liver in humans. *Surgery, Gynecology & Obstetrics*, 117(5), 659–676.

[32] Topol, E. (2019). *Deep medicine: How artificial intelligence can make healthcare human again.* Basic Books.

[33] Webster, C. (2002). *The National Health Service: A political history*. Oxford University Press.

[34] Welch, H. G., Schwartz, L. M., & Woloshin, S. (2011). *Overdiagnosed: Making people sick in the pursuit of health.* Beacon Press.

[35] World Health Organization. (2023). *Global strategy on digital health 2020–2025*. https://www.who.int/publications/i/item/9789240020924

[36] World Health Organization. (2023). *Universal health coverage (UHC)*. https://www.who.int/news-room/fact-sheets/detail/universal-health-coverage-(uhc)

[37] World Health Organization. (2023). *Immunization coverage*. https://www.who.int/news-room/fact-sheets/detail/immunization-coverage

[38] Zhou, X., Richmond, B. A., & Lowenthal, D. T. (2006). Biomarkers and cardiovascular risk assessment. *The American Journal of Geriatric Cardiology*, 15(4), 182–189. https://doi.org/10.1111/j.1076-7460.2006.05219.x